MP14: Prostate Cancer: Advanced (including Drug Therapy) II
304B
Poster and Podium Sessions
Oncology: Prostate
Information
Continuing Medical Education
CME
Friday, May 3
MP14-01: Rates and Predictors of False Node-Positive PSMA-PET in Patients Treated With Radical Prostatectomy and Extend Pelvic Lymph-Node Dissection: Results From a Large, Multi-Institutional Database
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-02: Identify the optimal candidates for adjuvant androgen deprivation therapy among patients with detectable PSA after radical prostatectomy.
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-03: A method of quantitative classification of metastatic castration-resistant prostate cancer and its signification and application
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-04: The Role Of PSA Doubling Time In The Stratification Of Patients With A Negative PSMA PET After Biochemical Recurrence Of Prostate Cancer: Implications For Tailored Salvage Treatment Strategies.
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-05: The impact of Upfront combination therapy in patients with mCSPC on OS after mCRPC: a multicentre retrospective study
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-06: Impact of abiraterone on sexual function in men with advanced prostate cancer: A meta-analysis of RCTs
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-07: Preferences for androgen deprivation therapies by prior hormonal treatment exposure in patients with prostate cancer: A discrete choice experiment
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-08: Real-word Clinical characterization of metastatic hormone sensitive prostate Cancer: Data from the European network of excellence for big data in prostate cancer (PIONEER).
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-09: Development of a Prediction model of Survival amongst patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) using big data: interim results from the European network of excellence for big data in prostate cancer (PIONEER).
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-10: Identifying The Optimal Candidate For Concomitant Androgen-Deprivation Therapy Among Patients Receiving Metastasis-Directed Therapy For Positive PSMA PET and Primary or Secondary Biochemical Recurrence from Prostate Cancer
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-11: The Added Value of concomitant Whole-Pelvis Salvage Radiation Therapy in oligo-recurrent prostate cancer patients treated with Metastasis-directed Therapy for Distant Positive Uptakes at PSMA PET
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-12: Exploring the dual impact to treatment outcomes in patients with short time to nadir PSA under androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-13: Exploring the interaction between the use of metastasis directed therapy in patients with positive PSMA PET and patterns of biochemical recurrence after radical prostatectomy. Results of a large, single Institution series
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-14: The impact of delayed administration of androgen-receptor signaling inhibitors (ARSI) on prognosis for mHNPC
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-15: Which Is the Optimal Multimodal Management of pN1 Patients with PSA Persistence After Radical Prostatectomy and Extended Nodal Dissection? Results of a Large, Multi-Institutional Database
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-16: Does the type of androgen deprivation therapy has an impact on pathohistology and oncological outcome for cytoreductive radical prostatectomy (cRP)?
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-18: Oncological Outcomes of pN1 Prostate Cancer Patients Treated with Radical Prostatectomy: Does Molecular Imaging Have a Prognostic Impact? Results of a Large, Multi-Institutional Series
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-19: ARV-766, a PROTAC androgen receptor (AR) degrader, combined with abiraterone in novel hormonal agent (NHA)-naïve metastatic prostate cancer: phase 1 cohort (part C) of a phase 1/2 study
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B
MP14-20: Enhancing Bone Health Screening for Prostate Cancer Patients Starting Androgen Deprivation Therapy: The Auto-Recruit Outpatient System
Friday, May 3, 2024 1:00 PM to 3:00 PM
304B